GH excess: Diagnosis and medical therapy

European Journal of Endocrinology

Volumn 170, Issue 1, 2014, Pages

  Andersen, Marianne ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; FETAL ANTIGEN; FETAL ANTIGEN 1; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; THYROTROPIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; HUMAN GROWTH HORMONE; IGF1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SOMATOSTATIN;

ACROMEGALY; BODY COMPOSITION; CANCER CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; GAMMA KNIFE RADIOSURGERY; GENETIC ANALYSIS; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; REVIEW; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG COMBINATION; GENETICS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; MUTATION; PATHOPHYSIOLOGY;

ACROMEGALY; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; HYPERPROLACTINEMIA; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; SOMATOSTATIN;

EID: 84893149702     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0532     Document Type: Review

References (107)

1. v.d.Lely AJ, Beckers A, Daly AF, Lamberts SW & Clemmons D. Acromegaly: a historical timeline. In Acromegaly. Pathology, Diagnosis and Treatment. edn. 1, ch. 1, pp. 3-25. Eds AJ v.d.Lely, A Beckers, AF Daly, SWLamberts & D Clemmons. NY: Taylor and Francis Group, 2005.
2. Wier J. Medicarum observatorium rararum, edn. 1, ch. 1, pp. 7-10. In Virgo Gygantea ex quartana reddita, pp 7-10. Basel, Switzerland: Oporinus, 1567.
3. Marie P. Sur deux cas d'acromégalie; hypertrophic singulière non congénitale des estrémités supérieures, inférieures et céphalique. Revue Médicale de Liége 1886 6 297-333.
4. Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ, Howlett TA et al. AIP mutation in pituitary adenomas in the 18th century and today. New England Journal of Medicine 2011 364 43-50. (doi:10.1056/NEJMoa1008020)
5. Barkan AL. Defining normalcy of the somatotropic axis: an attainable goal? Pituitary 2007 10 135-139. (doi:10.1007/s11102-007-0029-7)
6. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocrine Reviews 1991 12 424-449. (doi:10.1210/edrv-12-4- 424)
7. Jansson C, Boguszewski CL, Rosberg S, Carlsson L & Albertsson-Wikland K. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clinical Chemistry 1997 43 950-956.
8. Andersen M, Petersen PH, Blaabjerg O, Hangaard J & Hagen C. Evaluation of growth hormone assays using ratio plots. Clinical Chemistry 1998 44 1032-1038.
9. Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD & Ho KK. Physiological and pharmacological regulation of 20-kDa growth hormone. American Journal of Physiology. Endocrinology and Metabolism 2002 283 E836-E843.
10. Lima GA, Gadelha MR, Strasburger CJ & Wu Z. Serum levels of 20K-hGH and 22K-hGH isoforms in acromegalic patients. Frontiers of Hormone Research 2010 38 87-93.
11. Dias ML, Vieira JG & Abucham J. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay. Growth Hormone & IGF Research 2013 23 13-18. (doi:10.1016/j.ghir.2012.11.001)
12. Jorgensen JO, Vahl N, Hansen TB, Skjaerbaek C, Fisker S, Orskov H, Hagen C & Christiansen JS. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. Clinical Endocrinology 1998 48 479-486. (doi:10.1046/j.1365-2265.1998.00424.x)
13. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 1999 96 7324-7329. (doi:10.1073/pnas.96.13.7324)
14. Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, Fenwick S, Webb A, Wark G, Pleasance S & Gurnell M. A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clinical Endocrinology 2013 78 424-430. (doi:10.1111/cen.12085)
15. Barkan AL, Beitins IZ & Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 1988 67 69-73. (doi:10.1210/jcem-67-1-69)
16. Faje AT & Barkan AL. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 2010 95 2486-2491. (doi:10.1210/jc.2009-2634)
17. Daughaday WH, Kapadia M & Mariz I. Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. Journal of Laboratory and Clinical Medicine 1987 109 355-363.
18. Juul A. Determination of insulin-like growth factor I in children: normal values and clinical use. Hormone Research 2001 55 (Suppl 2) 94-99. (doi:10.1159/000063483)
19. Frystyk J, Freda P & Clemmons DR. The current status of IGF-I assays - a 2009 update. Growth Hormone & IGF Research 2010 20 8-18. (doi:10.1016/j.ghir.2009.09.004)
20. Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebae NE & Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. Journal of Clinical Endocrinology and Metabolism 1995 80 1407-1415. (doi:10.1210/jc.80.4.1407)
21. Frystyk J, Brick DJ, Gerweck AV, Utz AL & Miller KK. Bioactive insulin-like growth factor-I in obesity. Journal of Clinical Endocrinology and Metabolism 2009 94 3093-3097. (doi:10.1210/jc.2009-0614)
22. Gallagher EJ & LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011 152 2546-2551. (doi:10.1210/en.2011-0231)
23. Andersen M, Brixen K, Hagen C, Frystyk J & Nielsen TL. Positive associations between serum levels of IGF-I and subcutaneous fat depots in young men. The Odense Androgen Study. Growth Hormone & IGF Research 2012 22 139-145. (doi:10.1016/j.ghir.2012.04.006)
24. Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A, Brixen K & Andersen M. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. Journal of Clinical Endocrinology and Metabolism 2009 94 4010-4015. (doi:10.1210/jc. 2009-0980)
25. Nielsen TL, Wraae K, Brixen K, Hermann AP, Andersen M & Hagen C. Prevalence of overweight, obesity and physical inactivity in 20- to 29-year-old, Danish men. Relation to sociodemography, physical dysfunction and low socioeconomic status: the Odense Androgen Study. International Journal of Obesity 2006 30 805-815. (doi:10.1038/sj.ijo.0803197)
26. Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN & Gallagher D. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 2334-2343. (doi:10.1210/jc.2007-2780)
27. Neggers SJ, Kopchick JJ, Jorgensen JO & van der Lely AJ. Hypothesis: extra-hepatic acromegaly: a new paradigm? European Journal of Endocrinology 2011 164 11-16. (doi:10.1530/EJE-10-0969)
28. Rotwein P. Mapping the growth hormone-Stat5b-IGF-I transcriptional circuit. Trends in Endocrinology and Metabolism 2012 23 186-193. (doi:10.1016/j.tem.2012.01.001)
29. Ho PJ, Friberg RD & Barkan AL. Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1992 75 812-819. (doi:10.1210/jc.75.3. 812)
30. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. Journal of Clinical Investigation 2003 112 1603-1618.
31. Alexandraki KI, Munayem KM, Chahal HS, Dalantaeva NS, Trivellin G, Berney DM, Caron P, Popovic V, Pfeifer M, Jordan S et al . Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones 2012 11 297-307.
32. Chesnokova V & Melmed S. Pituitary senescence: the evolving role of Pttg. Molecular and Cellular Endocrinology 2010 326 55-59. (doi:10.1016/j.mce. 2010.02.012)
33. Daly AF, Tichomirowa MA & Beckers A. The epidemiology and genetics of pituitary adenomas. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 543-554. (doi:10.1016/j.beem.2009.05.008)
34. Trivellin G & Korbonits M. AIP and its interacting partners. Journal of Endocrinology 2011 210 137-155. (doi:10.1530/JOE-11-0054)
35. Beckers A, Aaltonen LA, Daly AF & Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrine Reviews 2013 34 239-277. (doi:10.1210/er.2012-1013)
36. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al . Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230. (doi:10.1126/science.1126100)
37. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 2390-2401. (doi:10.1210/jc.2007-2611)
38. Chahal HS, Chapple JP, Frohman LA, Grossman AB & Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends in Endocrinology and Metabolism 2010 21 419-427. (doi:10.1016/j.tem.2010.02.007)
39. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology 2011 165 509-515. (doi:10.1530/EJE-11-0304)
40. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A & Chanson P. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. Journal of Clinical Endocrinology and Metabolism 2012 97 E663-E670. (doi:10.1210/jc.2011-2291)
41. Belar O, De la Hoz C, Perez-Nanclares G, Castano L & Gaztambide S. Novel mutations in Men1, CDKN1b and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clinical Endocrinology 2012 76 719-724. (doi:10.1111/j.1365-2265.2011.04269.x)
42. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Molecular and Cellular Endocrinology 2013.
43. Fay TN, Jacobs I, Teisner B, Poulsen O, Chapman MG, Stabile I, Bohn H, Westergaard JG & Grudzinskas JG. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1988 29 73-85. (doi:10.1016/0028-2243(88) 90167-0)
44. Traustadottir GA, Kosmina R, Sheikh SP, Jensen CH & Andersen DC. Preadipocytes proliferate and differentiate under the guidance of delta-like 1 homolog (DLK1). Adipocytes 2013 2 272-275. (doi:10.4161/adip.24994)
45. Smas CM, Chen L & Sul HS. Cleavage of membrane-associated pref-1 generates a soluble inhibitor of adipocyte differentiation. Molecular and Cellular Biology 1997 17 977-988.
46. Nakakura T, Sato M, Suzuki M, Hatano O, Takemori H, Taniguchi Y, Minoshima Y & Tanaka S. The spatial and temporal expression of delta-like protein 1 in the rat pituitary gland during development. Histochemistry and Cell Biology 2009 131 141-153. (doi:10.1007/s00418-008-0494-8)
47. Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B & Klibanski A. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. American Journal of Pathology 2011 179 2120-2130. (doi:10.1016/j.ajpath.2011.07.002)
48. Andersen M, Jensen CH, Stoving RK, Larsen JB, Schroder HD, Teisner B & Hagen C. Fetal antigen 1 in healthy adults and patients with pituitary disease: relation to physiological, pathological, and pharmacological GH levels. Journal of Clinical Endocrinology and Metabolism 2001 86 5465-5470. (doi:10.1210/jc.86.11.5465)
49. Jensen CH, Krogh TN, Stoving RK, Holmskov U & Teisner B. Fetal antigen 1 (FA1), a circulating member of the epidermal growth factor (EGF) superfamily: ELISA development, physiology and metabolism in relation to renal function. Clinica Chimica Acta 1997 268 1-20. (doi:10.1016/S0009-8981(97)00152- 6)
50. Falkheden T & Wickbom I. Renal function and kidney size following hypophysectomy in man. Acta Endocrinologica 1965 48 348-354.
51. Andersen M, Hansen TB, Bollerslev J, Bjerre P, Schroder HD & Hagen C. Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study. Journal of Endocrinological Investigation 1995 18 840-846.
52. Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B & Schopohl J. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. European Journal of Endocrinology 2013 168 39-47. (doi:10.1530/EJE-12-0602)
53. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD & Vance ML. Pituitary incidentaloma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 894-904. (doi:10.1210/jc.2010-1048)
54. Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG & Birkenhager JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. European Journal of Clinical Investigation 1982 12 151-155. (doi:10.1111/j.1365-2362. 1982.tb00952.x)
55. Andersen M, Ganc-Petersen J, Jorgensen JO, Mellemkjaer S, Petersen PH, Blaabjerg O & Hagen C. Hypersecretion of the α-subunit in clinically non-functioning pituitary adenomas: diagnostic accuracy is improved by adding α-subunit/gonadotropin ratio to levels of α-subunit. Clinical and Investigative Medicine 2010 33 E203-E212.
56. Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N & Randall RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clinic Proceedings 1990 65 461-474. (doi:10.1016/S0025- 6196(12)60946-X)
57. Vidal S, Horvath E, Kovacs K, Lloyd RV & Smyth HS. Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia. Modern Pathology 2001 14 20-28. (doi:10.1038/modpathol. 3880252)
58. Andersen M, Hagen C, Frystyk J, Schroeder HD & Hagen C. Development of acromegaly in patients with prolactinomas. European Journal of Endocrinology 2003 149 17-22. (doi:10.1530/eje.0.1490017)
59. Asa SL, Kovacs K, Horvath E, Singer W & Smyth HS. Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line. Journal of Clinical Endocrinology and Metabolism 1992 75 68-75. (doi:10.1210/jc.75.1. 68)
60. Feigenbaum SL, Downey DE, Wilson CB & Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. Journal of Clinical Endocrinology and Metabolism 1996 81 1711-1719. (doi:10.1210/jc.81.5.1711)
61. Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, Qu X, Han T, Qu Y & Xu G. The characteristics of acromegalic patients with hyperprolactinemia and the differences with patients with merely GH-secreting adenomas: clinical analysis of 279 cases. European Journal of Endocrinology 2012 166 797-802. (doi:10.1530/EJE-11-1119)
62. Sakharova AA, Dimaraki EV, Chandler WF & Barkan AL. Clinically silent somatotropinomas may be biochemically active. Journal of Clinical Endocrinology and Metabolism 2005 90 2117-2121. (doi:10.1210/jc.2004-0875)
63. Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P & Heald AH. Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Annals of Clinical Biochemistry 2007 44 89-93. (doi:10.1258/000456307779596075)
64. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
65. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
66. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D et al. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740. (doi:10.1530/eje.1.02036)
67. Carmichael JD & Bonert VS. Medical therapy: options and uses. Reviews in Endocrine & Metabolic Disorders 2008 9 71-81. (doi:10.1007/s11154-007- 9068-7)
68. Jayasena CN, Wujanto C, Donaldson M, Todd JF & Meeran K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clinical Endocrinology 2008 68 36-41. (doi:10.1111/j.1365- 2265.2007.02996.x)
69. Markkanen H, Pekkarinen T, Valimaki MJ, Alfthan H, Kauppinen-Makelin R, Sane T & Stenman UH. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clinical Chemistry 2006 52 468-473. (doi:10.1373/clinchem.2005.060236)
70. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM & Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 1613-1617. (doi:10.1210/jc.2003-031584)
71. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734. (doi:10.1210/jc.83.8.2730)
72. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
73. Andries M, Glintborg D, Kvistborg A, Hagen C & Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clinical Endocrinology 2008 68 473-480. (doi:10.1111/j.1365-2265.2007.03067.x)
74. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I & Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 2012 7 e36411. (doi:10.1371/journal.pone.0036411)
75. Mazziotti G & Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010 13 60-67. (doi:10.1007/s11102-009-0169-z)
76. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA & van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. European Journal of Endocrinology 2005 153 67-71. (doi:10.1530/eje.1.01935)
77. Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J & Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 2012 77 72-78. (doi:10.1111/j.1365- 2265.2011.04286.x)
78. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2013 98 E66-E71. (doi:10.1210/jc.2012-2609)
79. Gadelha MR, Kasuki L & Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology and Metabolism 2013 24 238-246. (doi:10.1016/j.tem.2012.11.007)
80. Auriemma RS, Pivonello R, Galdiero M, De Martino MC, De Leo M, Vitale G, Lombardi G & Colao A. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. Journal of Endocrinological Investigation 2008 31 956-965.
81. Colao A, Auriemma RS, Galdiero M, Lombardi G & Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Journal of Clinical Endocrinology and Metabolism 2009 94 3746-3756. (doi:10.1210/jc.2009-0941)
82. Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL & Bollerslev J. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clinical Endocrinology 2011 74 736-743. (doi:10.1111/j.1365-2265.2011.03982.x)
83. Li ZQ, Quan Z, Tian HL & Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. Journal of International Medical Research 2012 40 517-524. (doi:10.1177/147323001204000213)
84. Grasso LF, Pivonello R & Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Current Opinion in Endocrinology, Diabetes, and Obesity 2012 19 288-294. (doi:10.1097/MED. 0b013e328354af67)
85. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 2010 95 2781-2789. (doi:10.1210/jc.2009-2272)
86. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV & Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992 256 1677-1680. (doi:10.1126/science.256.5064.1677)
87. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
88. Besser GM, Burman P & Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187-193. (doi:10.1530/eje.1.01968)
89. Neggers SJ & van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Hormone & IGF Research 2011 21 129-133. (doi:10.1016/j.ghir.2011.03.004)
90. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M & Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 2013 98 3446-3453. (doi:10.1210/jc.2013-1771)
91. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C & Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631. (doi:10.1210/jc.2005-0531)
92. Burt MG & Ho KK. Newer options in the management of acromegaly. Internal Medicine Journal 2006 36 437-444. (doi:10.1111/j.1445-5994.2006.01097. x)
93. Roth BL. Drugs and valvular heart disease. New England Journal of Medicine 2007 356 6-9. (doi:10.1056/NEJMp068265)
94. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
95. Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M & Colao AA. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. European Journal of Endocrinology 2013 169 359-366. (doi:10.1530/EJE-13-0231)
96. Steffensen C, Maegbaek ML, Laurberg P, Andersen M, Kistorp CM, Norrelund H, Toft SH & Lunde Jorgensen JO. Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. Journal of Clinical Endocrinology and Metabolism 2012 97 1629-1634. (doi:10.1210/jc.2011- 3257)
97. Maione L, Garcia C, Bouchachi A, Kallel N, Maison P, Salenave S, Young J, Assayag P& Chanson P. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2012 97 E1714-E1719. (doi:10.1210/jc.2012-1833)
98. Sandret L, Maison P & Chanson P. Place of cabergoline in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2011 96 1327-1335. (doi:10.1210/jc.2010-2443)
99. McCormack AI, Wass JA & Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation 2011 41 1133-1148. (doi:10.1111/j.1365-2362.2011.02520.x)
100. Friedman HS, Kerby T & Calvert H. Temozolomide and treatment of malignant glioma. Clinical Cancer Research 2000 6 2585-2597.
101. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J & Brue T. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology 2012 76 769-775. (doi:10.1111/j.1365-2265.2012.04381.x)
102. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV & Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 2010 13 367-379. (doi:10.1007/s11102-010-0249-0)
103. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr & Lopes MB. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. Journal of Clinical Endocrinology and Metabolism 2010 95 E280-E290. (doi:10.1210/jc.2010- 0441)
104. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592-4599. (doi:10.1210/jc.2010-0644)
105. Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J & Tauveron I. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Investigation 2013 31 190-196. (doi:10.3109/07357907.2013.775293)
106. Hagen C, Schroeder HD, Hansen S, Hagen C & Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. European Journal of Endocrinology 2009 161 631-637. (doi:10.1530/EJE-09-0389)
107. Whitelaw B, Dworakowska D, Thomas N, Barazi S, Riordan-Eva P, King A, Hampton T, Landau D, Lipscomb D, Buchanan C et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clinical Endocrinology 2012 76 877-886. (doi:10.1111/j.1365-2265.2012.04373.x)